Azura Ophthalmics

Executive Summary

Azura Ophthalmics is a preclinical Israeli biotech developing first-in-class keratolytic therapies for lid margin and ocular surface diseases, such as blepharitis and meibomian gland dysfunction. By targeting abnormal keratinization—a root cause of these conditions—the company aims to reduce signs, symptoms, and patient burden. Founded in 2020, Azura leverages a novel mechanism distinct from existing anti-inflammatory or antibiotic approaches. The company is currently advancing lead candidates through IND-enabling studies, with a focus on generating preclinical proof-of-concept data. While still early-stage and private, Azura addresses a large underserved market with no approved keratolytic agents. Successful development could offer the first disease-modifying therapy for chronic lid margin disease. The company’s experienced management and scientific advisors enhance its credibility, though the preclinical stage carries high technical and regulatory risk. Upcoming milestones include presentation of in vivo efficacy data and completion of toxicology studies, which will inform the path to first-in-human trials.

Upcoming Catalysts (preview)

• Q2 2026Preclinical data presentation at ARVO 202665% success
• Q1 2027IND submission for lead candidate35% success
• Q4 2026Series A financing round50% success